欢迎访问西安瑞禧生物技术有限公司官方网站

图片名

全国订购热线:
18966759382

首页 > 定制合成 > 其他产品

其他产品
小分子PEG 嵌段共聚物 纳米材料 糖化学 荧光量子点 其他产品

「同位素标记抑制剂」(Rac)-Rotigotine-d7 hydrochloride

作者:瑞禧生物 发布时间:2025-07-08 09:23:37 次浏览

生物活性:(Rac)-Rotigotine-d7 (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.
IC50 & Target:D1 Receptor
D3 Receptor
D4 Receptor
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
(Rac)-Rotigotine-d7 hydrochloride 相关抗体:
ADRB2 Antibody
DRD2 Antibody
MTNR1A Antibody
Dopamine Receptor D3 Antibody (YA1742)
DOPA Decarboxylase Antibody (YA2428)
Dopamine Receptor D1 Antibody (YA3270)
Salbutamol Antibody (YA901)
Clenbuterol Antibody (YA904)
alpha 1a Adrenergic Receptor Antibody (YA2059)
Torsin 1A Antibody (YA2935)
PITX3 Antibody (YA2974)
HMBS Antibody (YA3061)
分子量:358.98
Formula:C19H19D7ClNOS
非标记 CAS:102120-99-0
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (529 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Wood M, et al. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol. 2015 Feb;172(4):1124-35.
 [Content Brief]
[3]. Scheller D, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73-86.
 [Content Brief]
[4].  Fenu S, et al. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors. Eur J Pharmacol. 2016 Oct 5;788:183-91.
 [Content Brief]
[5]. Radad K, et al. Neuroprotective effect of rotigotine against complex I inhibitors, MPP+ and rotenone, in primary mesencephalic cell culture. Folia Neuropathol. 2014;52(2):179-86.
 [Content Brief]